- Home
- GAU vs CTMX Comparison
GAU vs CTMX Comparison
Compare GAU & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAU
- CTMX
- Stock Information
- Founded
- GAU 1999
- CTMX 2008
- Country
- GAU Canada
- CTMX United States
- Employees
- GAU N/A
- CTMX N/A
- Industry
- GAU
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- GAU
- CTMX Health Care
- Exchange
- GAU Nasdaq
- CTMX Nasdaq
- Market Cap
- GAU 731.5M
- CTMX 596.2M
- IPO Year
- GAU N/A
- CTMX 2015
- Fundamental
- Price
- GAU $2.18
- CTMX $3.67
- Analyst Decision
- GAU Strong Buy
- CTMX Strong Buy
- Analyst Count
- GAU 2
- CTMX 6
- Target Price
- GAU $3.00
- CTMX $6.50
- AVG Volume (30 Days)
- GAU 2.7M
- CTMX 3.8M
- Earning Date
- GAU 11-06-2025
- CTMX 11-06-2025
- Dividend Yield
- GAU N/A
- CTMX N/A
- EPS Growth
- GAU N/A
- CTMX 50.22
- EPS
- GAU N/A
- CTMX 0.24
- Revenue
- GAU $352,642,000.00
- CTMX $113,631,000.00
- Revenue This Year
- GAU $84.10
- CTMX N/A
- Revenue Next Year
- GAU $50.80
- CTMX N/A
- P/E Ratio
- GAU N/A
- CTMX $15.15
- Revenue Growth
- GAU 111.43
- CTMX N/A
- 52 Week Low
- GAU $1.00
- CTMX $0.40
- 52 Week High
- GAU $3.12
- CTMX $4.62
- Technical
- Relative Strength Index (RSI)
- GAU 41.74
- CTMX 50.63
- Support Level
- GAU $2.12
- CTMX $3.42
- Resistance Level
- GAU $2.25
- CTMX $4.45
- Average True Range (ATR)
- GAU 0.14
- CTMX 0.38
- MACD
- GAU -0.02
- CTMX -0.07
- Stochastic Oscillator
- GAU 41.39
- CTMX 24.02
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.